Who Should Use Penile Traction Therapy | SizeGenetics

Episode SummaryWho should use penile traction therapy — and who shouldn't? This episode breaks down the three evidence-based candidate groups, key contraindications, and what the clinical literature reveals about proper patient selection for penile traction therapy.Key FindingsThree candidate groups: Chronic-phase Peyronie's disease, post-prostatectomy rehabilitation, and medically assessed length concerns2023 Meta-Analysis (Almsaoud et al.): 12 studies, 1,000+ patients, 1.9 cm mean length gain and 27% curvature improvementToussi 2021 RCT: Post-prostatectomy patients gained 1.6 cm vs. 0.3 cm in controls, with 93% recommending the therapyAdherence threshold: 4–6 hours daily for 3–6 months required for meaningful outcomesSafety profile: Adverse events 11.2–14.4%, all mild and temporary, no serious events reportedThe SciencePenile traction therapy works through mechanotransduction — the cellular response to sustained mechanical tension that triggers collagen remodeling and tissue expansion. Proper candidacy and adherence are essential to achieve the therapeutic response documented in clinical studies.About SizeGeneticsFDA-registered Class II medical device, manufactured by Danamedic ApS in Denmark since 1994. Delivers calibrated tension of 900–2,800 grams — the exact therapeutic range used in clinical studies. Over 1 million units sold worldwide.ResourcesFull Guide: Who Should Use Penile Traction TherapyPeyronie's Disease TreatmentPost-Surgical RehabilitationSafety Profile and Adverse EventsTreatment Protocol GuideMedical Disclaimer: This content is for educational purposes only and does not constitute medical advice. Consult a qualified healthcare professional before starting any treatment.